Skip to main content

Table 1 Baseline characteristics of AFNET patients

From: Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry

 

AF patients without prior stroke or TIA n = 8,649

AF patients with prior stroke or TIA n = 896

p

Age, years, mean (SD) [range]

68.1 (11.1) [18–98]

71.3 (9.6) [24–94]

<0.0001

Male, % (n)

61.3 (5,306)

57.1 (512)

<0.05

Atrial fibrillation, % (n)a

  

<0.0001

First detected

11.4 (983)

6.1 (55)

<0.001

Paroxysmal

31.7 (2,737)

26.3 (236)

<0.001

Persistent

20.1 (1,739)

21.0 (188)

0.540

Permanent

34.3 (2,967)

43.1 (386)

<0.001

Unknown

2.5 (219)

3.5 (31)

0.113

Mitral valve stenosis, % (n)

2.0 (177)

3.8 (34)

<0.001

Valvular replacement, % (n)

5.1 (440)

5.7 (51)

0.44

Heart failure, % (n)

35.4 (2,877)a

43.7 (370)a

<0.0001

Diabetes mellitus, % (n)

21.1 (1,828)

27.1 (243)

<0.0001

Arterial hypertension, % (n)

68.7 (5,938)

75.8 (679)

<0.0001

Coronary artery disease, % (n)

27.2 (2,120)a

39.0 (309)a

<0.0001

Peripheral artery disease, % (n)

6.5 (537)a

11.0 (93)a

<0.0001

Hyperlipidemia, % (n)

45.2 (3,431)a

55.2 (424)a

<0.0001

Chronic renal failure, % (n)

11.0 (907)a

18.7 (159)a

<0.0001

  1. an < 8,649 or n < 896, respectively
  2. Baseline characteristics of AF patients with or without prior ischaemic stroke or TIA on enrolment to the AFNET registry